 |
| Weekly Journal Scans | More » |
 |
Treatment-Response Monitoring Using PET in Esophageal Carcinoma
Eur J Surg Oncol, 2009 Oct 1, SA Suttie , et al
Review of 22 studies reveals variations in the ability to predict pathologic response and survival outcomes using PET data.
|
CML With P190BCR-ABL Shows Poor Response to TKI Therapy
Blood, 2009 Sept 21, D Verma, et al
Although the P190BCR-ABL transcript in CML is rare (1%), it is associated with an inferior outcome to tyrosine kinase inhibitors.
|
New-Variant VH4-34+ Hairy Cell Leukemia Has a Poor Prognosis
Blood, 2009 Sept 10, E Arons , et al
VH4-34 status relates to poorer response to cladribine and shorter survival among patients with the hairy cell leukemia variant.
|
Predicting Delayed PSA Recurrence After Radical Prostatectomy
Urology, 2009 Sept 1, AA Caire, et al
Lower pathologic Gleason scores and lower PSA at diagnosis were associated with delayed PSA recurrence.
|
Serum CA-125 Predicts Pathologic Outcome After Cystectomy for Bladder Carcinoma 
Urol Oncol, 2009 Sept 1, EJ Kouba, et al
Among patients treated with radical cystectomy, CA-125 was a useful indicator of tumor staging, resectability, and recurrence.
|
Outcomes From Laparoscopic Radical Nephrectomy Correlate With Patient Factors
Urology, 2009 Sept 1, AH Gabr, et al
BMI, American Society of Anesthesiologists score, and age, rather than tumor characteristics, were associated with perioperative outcomes.
|
SEER-Derived Survival Trends in Stage IIIB and IV NSCLC
Chest, 2009 Sept 1, WN William, Jr, et al
Subgroups of patients with stage IIIB or IV NSCLC demonstrate heterogeneous rates of survival.
|
Pemetrexed-Carboplatin Is Inferior to Etoposide-Carboplatin in Advanced SCLC
J Clin Oncol, 2009 Aug 31, MA Socinski, et al
The GALES study was stopped early when an interim analysis revealed inferior OS with pemetrexed-carboplatin vs etoposide-carboplatin.
|
| Weekly Review Articles | More » |
|
Breast Cancer Molecular Subtype Determines Outcomes in Locally Advanced Disease
Semin Radiat Oncol, 2009 Oct 1, KE Huber, et al
Luminal A, luminal B, basal-like, and HER2-enriched subtypes of breast cancer may have different treatment responses and outcomes.
|
Inflammatory Breast Cancer: Clinicopathology and Multimodality Treatment
Semin Radiat Oncol, 2009 Oct 1, WA Woodward, et al
This review examines the unique epidemiology and pathology of IBC and the importance of a multimodality treatment approach.
|
Infections in Patients With Aplastic Anemia Treated With Immunosuppressants
Semin Hematol, 2009 Jul 1, JM Valdez, et al
The major fungal, bacterial, parasite, and viral infections found in immunosuppressed patients with AA are discussed.
|
|
| | |
| ECCO/ESMO 2009
Conference news plus interviews with ECCO/ESMO officers.
VISIT SITE
| |
|
|
| | |
| CANCER POLICY FORUM
Get behind-the-headline perspectives on the politics of cancer.
VISIT SITE
| |
|
|
| | |
| WHEN THE SMOKE CLEARS
Experts discuss the true clinical implications of watershed developments in oncology research.
VISIT SITE
| |
|
|
| | |
| RELATED WEBSITES
These websites offer more information on a variety of oncology-related topics.
VISIT SITE
| |
|
|
| | |
| VIDEOS
Watch video interviews with leading cancer experts.
VISIT SITE
| |
|
|
|
A Week in Review
